Checkpoint Therapeutics, Inc. ("Checkpoint") is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development, and commercialization of treatments for patients with solid tumor cancers.
Company (Alive / Active)
Phone: 781-652-4500
2 Gansevoort Street
9th Floor
New York, 10014
New York, United States
Per Week | Per Month | Per 6 Months | Per Year | |
---|---|---|---|---|
Rank | Login to see details | |||
Page Views Per Million | Login to see details | |||
Page Views Per User | Login to see details | |||
Reach Per Million | Login to see details |
Title | Application Date | Patent Date | Status (Patent / Application) |
---|---|---|---|
Pd-l1-specific antibodies and methods of using the same | Jun 28, 2017 | Mar 17, 2020 | Patent |
Pd-l1-specific antibodies and methods of using the same | Mar 13, 2020 | Application |